Abstract
The role of the host immune compartment in the control of chronic myeloid leukaemia (CML) has been suggested by numerous biological and clinical evidence. In the present study, the phenotypic and functional machinery of both T and cytotoxic lymphocytes was evaluated in a series of CML patients in complete haematological, and frequently also in cytogenetic, remission after treatment with interferon (IFN) alpha or hydroxyurea, and compared with the profile observed in patients at diagnosis and in normal controls. In particular, the lymphocyte subset distribution, the cytotoxic activity and the intracellular production of tumour necrosis factor (TNF)alpha and IFN gamma by CD4(+), CD8(+) and CD56(+) cells were investigated. CML patients in complete haematological remission showed a normalized CD4/CD8 T-cell subset distribution, as well as a restored spontaneous and interleukin 2 (IL-2) induced cytotoxic function compared with the pattern observed at diagnosis. This was associated with a significantly increased proportion of activated CD4(+) lymphocytes (CD25(+)). TNF alpha and IFN gamma production by CD4(+), CD8(+) and CD56(+) lymphocytes was significantly enhanced compared with that of patients at diagnosis. However, the values we...Continue Reading
References
Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S A KliewerR M Evans
Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·W ChenM A Cheever
Jun 1, 1988·Annals of Internal Medicine·J M GoldmanP B McGlave
Sep 1, 1995·British Journal of Haematology·A HochhausN C Cross
Oct 1, 1994·The Journal of Clinical Investigation·M TalpazR Kurzrock
Mar 24, 1994·The New England Journal of Medicine·UNKNOWN Italian Cooperative Study Group on Chronic Myeloid LeukemiaMauro Fiacchini
Mar 1, 1996·Cancer Immunology, Immunotherapy : CII·G PawelecP da Silva
Jun 1, 1996·British Journal of Haematology·Y Z JiangA J Barrett
Aug 29, 1997·The Journal of Experimental Medicine·Y Itoh, R N Germain
Mar 31, 1998·Leukemia·T OkaR B Arlinghaus
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·O MandelboimJ L Strominger
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockM Talpaz
May 20, 1998·Current Topics in Microbiology and Immunology·T L WhitesideR B Herberman
Oct 31, 1998·Current Opinion in Immunology·D M Pardoll, S L Topalian
Mar 23, 1999·British Journal of Haematology·D de ToteroR Foa
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Jul 15, 1999·The New England Journal of Medicine·S FaderlH M Kantarjian
Sep 15, 1999·Nature·M K SlifkaJ L Whitton
Nov 25, 2000·British Journal of Haematology·E K ChoN K Kim
Citations
Sep 10, 2005·Leukemia·H GaoJ M Reuben
Dec 11, 2002·British Journal of Haematology·Atsushi IsodaMasamitsu Karasawa
Dec 21, 2002·British Journal of Haematology·Klaus EisendleGuenther Gastl
Mar 26, 2008·Pediatric Hematology and Oncology·Salvador MartiGonzalo Rubio
Jan 29, 2010·Immunopharmacology and Immunotoxicology·Abhilasha AgarwalSunita Saxena
Feb 13, 2004·Leukemia & Lymphoma·Fabiola Attié de CastroJúlio César Voltarelli
Sep 21, 2013·Cancer Investigation·Xielan ZhaoFangping Chen
Mar 11, 2006·Leukemia Research·Enrica OrsiniRobert Foa
Jan 5, 2011·Clinical & Developmental Immunology·Zuzana HumlováVladimír Vonka
Jan 19, 2017·Current Opinion in Hematology·Michael J Mauro
Jun 11, 2004·Leukemia·K CwynarskiF Dazzi
Apr 15, 2003·Leukemia·N PanoskaltsisS C Knight
Jul 16, 2005·Leukemia & Lymphoma·Klaus EisendleBrigitte Kircher-Eibl